Although further understanding of the mechanisms that underlie the role of CSCs in the progression of HCC are required, our study provides proof of concept for the use of ALK5 inhibitors as potential therapeutic agents for HCC that act via the inhibition of FAK activation. The gene discussed is TGFBR1; the disease is hepatocellular carcinoma.